AN2 Therapeutics, Inc. (ANTX)

NMS – Real vaqt narxi. Valyuta: USD

6.36

+0.48 (8.26%)

Bozor ochiq: Aug 12, 2026, 3:11 PM EDT

5.87

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:45 PM EDT

11.08.2026

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the second quarter ended June 30, 2026. “AN2 will have three Phase 2 programs underway by the end of this year, all of which have the potential to address major unmet needs. Our near-term focus is advancing start-up activi.

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

AN2 Therapeutics, Inc. (ANTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Videolar

No Data

Press-relizlar

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Videolar

No Data

Press-relizlar

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Search stocks

AN2 Therapeutics, Inc. (ANTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Videolar

No Data

Press-relizlar

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Videolar

No Data

Press-relizlar

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights